|
1
|
Kochenderfer JN, Dudley ME, Kassim SH,
Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ,
Hughes MS, Sherry RM, et al: Chemotherapy-refractory diffuse large
B-cell lymphoma and indolent B-cell malignancies can be effectively
treated with autologous T cells expressing an anti-CD19 chimeric
antigen receptor. J Clin Oncol. 33:540–549. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rizvi NA, Mazières J, Planchard D,
Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E,
Mennecier B, et al: Activity and safety of nivolumab, an anti-PD-1
immune checkpoint inhibitor, for patients with advanced, refractory
squamous non-small-cell lung cancer (CheckMate 063): A phase 2,
single-arm trial. Lancet Oncol. 16:257–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sharma P and Allison JP: The future of
immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Postow MA, Callahan MK and Wolchok JD:
Immune checkpoint blockade in cancer therapy. J Clin Oncol.
33:1974–1982. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Postow MA: Managing immune
checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ
Book. 76–83. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Amitani M, Amitani H, Sloan RA, Suzuki H,
Sameshima N, Asakawa A, Nerome Y, Owaki T, Inui A and Hoshino E:
The translational aspect of complementary and alternative medicine
for cancer with particular emphasis on Kampo. Front Pharmacol.
6:1502015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamakawa J, Motoo Y, Moriya J, Ogawa M,
Uenishi H, Akazawa S, Sasagawa T, Nishio M and Kobayashi J: Role of
Kampo medicine in integrative cancer therapy. Evid Based Complement
Alternat Med. 2013:5708482013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Horie Y, Kato K, Kameoka S and Hamano K:
Bu ji (hozai) for treatment of postoperative gastric cancer
patients. Am J Chin Med. 22:309–319. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Niwa K, Hashimoto M, Morishita S, Lian Z,
Tagami K, Mori H and Tamaya T: Preventive effects of Juzen-taiho-to
on N-methyl-N-nitrosourea and estradiol-17beta-induced endometrial
carcinogenesis in mice. Carcinogenesis. 22:587–591. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dai Y, Kato M, Takeda K, Kawamoto Y,
Akhand AA, Hossain K, Suzuki H and Nakashima I:
T-cell-immunity-based inhibitory effects of orally administered
herbal medicine juzen-taiho-to on the growth of primarily developed
melanocytic tumors in RET-transgenic mice. J Invest Dermatol.
117:694–701. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ohnishi Y, Fujii H, Hayakawa Y, Sakukawa
R, Yamaura T, Sakamoto T, Tsukada K, Fujimaki M, Nunome S, Komatsu
Y and Saiki I: Oral administration of a Kampo (Japanese herbal)
medicine Juzen-taiho-to inhibits liver metastasis of colon 26-L5
carcinoma cells. Jpn J Cancer Res. 89:206–213. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Onishi Y, Yamaura T, Tauchi K, Sakamoto T,
Tsukada K, Nunome S, Komatsu Y and Saiki I: Expression of the
anti-metastatic effect induced by Juzen-taiho-to is based on the
content of Shimotsu-to constituents. Biol Pharm Bull. 21:761–765.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Matsuda T, Maekawa K, Asano K and
Hisamitsu T: Suppressive effect of juzen-taiho-to on lung
metastasis of b16 melanoma cells in vivo. Evid Based Complement
Alternat Med. 2011:7431532011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tsuchiya M, Kono H, Matsuda M, Fujii H and
Rusyn I: Protective effect of Juzen-taiho-to on
hepatocarcinogenesis is mediated through the inhibition of Kupffer
cell-induced oxidative stress. Int J Cancer. 123:2503–2511. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kamei T, Kumano H, Iwata K, Nariai Y and
Matsumoto T: The effect of a traditional Chinese prescription for a
case of lung carcinoma. J Altern Complement Med. 6:557–559. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Scheid V, Bensky D, Ellis A and Barolet R:
Chinese Herbal Medicine Formulas & Strategies. Eastland Press,
Inc.; Seattle, WA: pp. 348–352. 2009
|
|
19
|
Suzuki T, Yamamoto A, Ohsawa M, Motoo Y,
Mizukami H and Makino T: Ninjin'yoeito and ginseng extract prevent
oxaliplatin-induced neurodegeneration in PC12 cells. J Nat Med.
69:531–537. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ando N: Blood making effect of
Ninjin-yoei-to (Ren-shen- yang-rong-tang) as monotherapy in
obesteric and gynecologic patient with anemia. Jpn J Orient Med.
50:461–470. 1999.
|
|
21
|
Miyazaki T, Uchino H, Kimura I, Saito H,
Shibata A, Takaku F, Nagai K, Niho Y, Matsuda T, Miura A, et al:
Effects of Ren-shen-yang-rong-tang (Japanese name:
Ninjin-youei-to), a traditional herbal medicine, on the
hematopoiesis in the patients with aplastic anemia. J Clin Ther
Med. 10:2591–2603. 1994.(In Japanese).
|
|
22
|
Ohmori S, Usui T, Yasuda N, Ohmori M,
Yamagishi M and Okuma M: Improvement of anemia by administration of
EK-108 [Chinese herbal medicine, Ren-Shen-Yang-Rong-Tang (Japanese
name, Ninjin-Yoei-To)] in a patient of myelodisplastic syndrome.
Jpn Pharmacol Ther. 20:361–365. 1992.
|
|
23
|
Motoo Y, Mouri H, Ohtsubo K, Yamaguchi Y,
Watanabe H and Sawabu N: Herbal medicine Ninjinyoeito ameliorates
ribavirin-induced anemia in chronic hepatitis C: A randomized
controlled trial. World J Gastroenterol. 11:4013–4017. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matsuo M, Tani T and Saiki I: Organ
selectivity of Juzen-taiho-to and Ninjin-yoei-to in the expression
of anti-metastatic efficacy. J Trad Med. 19:93–97. 2002.
|
|
25
|
Kiyohara H, Nagai T, Munakata K, Nonaka K,
Hanawa T, Kim SJ and Yamada H: Stimulating effect of Japanese
herbal (kampo) medicine, hochuekkito on upper respiratory mucosal
immune system. Evid Based Complement Alternat Med. 3:459–467. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matsumoto T, Noguchi M, Hayashi O, Makino
K and Yamada H: Hochuekkito, a Kampo (traditional Japanese herbal)
medicine, enhances mucosal IgA antibody response in mice immunized
with antigen-entrapped biodegradable microparticles. Evid Based
Complement Alternat Med. 7:69–77. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Underwood JR, Chivers M, Dang TT and
Licciardi PV: Stimulation of tetanus toxoid-specific immune
responses by a traditional Chinese herbal medicine. Vaccine.
27:6634–6641. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Licciardi PV and Underwood JR:
Identification of a novel vaccine adjuvant that stimulates and
maintains diphtheria toxoid immunity. Vaccine. 28:3865–3873. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Taguchi A, Kawana K, Yokoyama T, Adachi K,
Yamashita A, Tomio K, Kojima S, Oda K, Fujii T and Kozuma S:
Adjuvant effect of Japanese herbal medicines on the mucosal type 1
immune responses to human papillomavirus (HPV) E7 in mice immunized
orally with Lactobacillus-based therapeutic HPV vaccine in a
synergistic manner. Vaccine. 30:5368–5372. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saiki I, Koizumi K, Goto H, Inujima A,
Namiki T, Raimura M, Kogure T, Tatsumi T, Inoue H, Sakai S, et al:
The long-term effects of a kampo medicine, juzentaihoto, on
maintenance of antibody titer in elderly people after influenza
vaccination. Evid Based Complement Alternat Med. 2013:5680742013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takeno N, Inujima A, Shinohara K, Yamada
M, Shibahara N, Sakurai H, Saiki I and Koizumi K: Immune adjuvant
effect of Juzentaihoto, a Japanese traditional herbal medicine, on
tumor vaccine therapy in a mouse model. Int J Oncol. 47:2115–2122.
2015.PubMed/NCBI
|
|
32
|
Takaku S, Terabe M, Ambrosino E, Peng J,
Lonning S, McPherson JM and Berzofsky JA: Blockade of TGF-beta
enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int J
Cancer. 126:1666–1674. 2010.PubMed/NCBI
|
|
33
|
Golgher D, Jones E, Powrie F, Elliott T
and Gallimore A: Depletion of CD25+ regulatory cells uncovers
immune responses to shared murine tumor rejection antigens. Eur J
Immunol. 32:3267–3275. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen ML, Pittet MJ, Gorelik L, Flavell RA,
Weissleder R, von Boehmer H and Khazaie K: Regulatory T cells
suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta
signals in vivo. Proc Natl Acad Sci USA. 102:419–424. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Casares N, Arribillaga L, Sarobe P, Dotor
J, de Lopez-Diaz Cerio A, Melero I, Prieto J, Borrás-Cuesta F and
Lasarte JJ: CD4+/CD25+ regulatory cells inhibit activation of
tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic
activity, as well as long-lasting tumor immunity elicited by
peptide vaccination. J Immunol. 171:5931–5939. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nagai T, Suzuki Y, Kiyohara H, Susa E,
Kato T, Nagamine T, Hagiwara Y, Tamura S, Yabe T, Aizawa C and
Yamada H: Onjisaponins, from the root of Polygala tenuifolia
Willdenow, as effective adjuvants for nasal influenza and
diphtheria- pertussis-tetanus vaccines. Vaccine. 19:4824–4834.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yasukawa K, Ikeya Y, Mitsuhashi H, Iwasaki
M, Aburada M, Nakagawa S, Takeuchi M and Takido M: Gomisin A
inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in
two-stage carcinogenesis in mouse skin. Oncology. 49:68–71. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nakai S, Kawakita T, Himeno K and Nomoto
K: Combined treatments with Ninjin-youei-to
(Ren-shen-yang-rong-tang) plus a suboptimal dose of prednisolone on
autoimmune nephritis in MRL/lpr mice. Int J Immunopharmacol.
20:275–284. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Terabe M, Ambrosino E, Takaku S, O'Konek
JJ, Venzon D, Lonning S, McPherson JM and Berzofsky JA: Synergistic
enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an
anti-transforming growth factor-beta monoclonal antibody. Clin
Cancer Res. 15:6560–6569. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Naidoo J, Page DB, Li BT, Connell LC,
Schindler K, Lacouture ME, Postow MA and Wolchok JD: Toxicities of
the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann
Oncol. 26:2375–2391. 2015.PubMed/NCBI
|
|
41
|
Medina PJ and Adams VR: PD-1 pathway
inhibitors: Immuno-oncology agents for restoring antitumor immune
responses. Pharmacotherapy. 36:317–334. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Choudhury N and Nakamura Y: Importance of
immunopharmacogenomics in cancer treatment: Patient selection and
monitoring for immune checkpoint antibodies. Cancer Sci.
107:107–115. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Saiki I: A Kampo medicine
‘Juzen-taiho-to’-prevention of malignant progression and metastasis
of tumor cells and the mechanism of action. Biol Pharm Bull.
23:677–688. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Takaku F, Yazaki Y, Kitahara M, Ueno F and
Echizen H: Manual of Therapeutic Agents. Igaku-shoin, Inc.; Tokyo,
Japan: pp. 23222016
|
